Introduction
With the availability in the late 1990s of ultrasensitive assays capable of quantifying plasma HIV-RNA levels down to 50 copies/ml, it became clear that a subset of HIV-infected patients had very low levels of viral replication despite years of infection without receiving antiretroviral therapy (ART). At different medical research centers where they are followed, these patients have been variably termed long-term nonprogressors (LTNP), elite controllers, elite suppressors or HIV controllers, but will be referred to as LTNP/elite controllers for the purposes of this review (recently reviewed in [1] ). The definitions of these patients have also varied among centers resulting in some differences in clinical characteristics and host genetics [1] . However, the majority of patients in these cohorts are characterized by sustained viral RNA levels below 50 copies/ml plasma in the absence of ART. Over the past 15 years, the HIV-specific immune responses of these patients have been extensively studied and compared with those targeting other viruses and the HIV-specific responses of progressors. In this review, we will discuss the background that led to the current understanding that HIV-specific CD8 þ T-cell responses in these patients are primarily responsible for suppressing HIV replication over many years. We will also discuss the much clearer picture that has recently emerged regarding the mechanism(s) by which CD8 þ T cells might mediate this effect.
Evidence for CD8
R T-cell mediated control of HIV in long-term nonprogressors/elite controllers There are several lines of evidence suggesting that host genetics and host immune response factors, not virus factors, are responsible for controlling HIV in LTNP/ elite controllers. For example, CD4 þ T cells from both progressors and LTNP/elite controllers appear to support equivalent levels of viral replication [2] [3] [4] . In addition, the viruses recovered from most LTNP/elite controllers are fully replication competent [5] . Although some minor defects in virus replication capacity have been observed, these are likely the result of immune selection pressure and not the cause of nonprogression [6] [7] [8] . In addition, there are examples of transmission to persons who became LTNP/elite controllers of viruses that were sufficiently pathogenic to cause disease progression in the transmitter [9] . Lastly, in a simian immunodeficiency virus (SIV)-infected rhesus macaque model of LTNP/ elite controllers, infection with a cloned SIVmac239 virus, that is highly pathogenic for most animals, can be controlled [10, 11] . Thus, the majority of the evidence suggests that control of HIV replication in most LTNP/ elite controllers is not a result of a diminished ability of their CD4
þ T cells to support viral replication or reduced viral replicative capacity.
The vast majority of evidence suggests that the HIVspecific CD8
þ T-cell response mediates immunologic control in LTNP/elite controllers. There is a dramatic overrepresentation of the human leukocyte antigen (HLA) class I alleles BÃ57 and BÃ27 in most cohorts of LTNP/elite controllers (reviewed in [1]). Similarly, associations between the protective major histocompatibility complex (MHC) alleles Mamu BÃ08 and BÃ17 and nonprogressor status have been found in LTNP/elite controller macaques [10, 11] . The importance of these associations between particular MHC alleles and immune control have been further supported by whole-genome association analyses, which have consistently revealed that the factors most strongly associated with nonprogressive HIV infection are either HLA class I alleles or single nucleotide polymorphisms that are in linkage disequilibrium with HLA BÃ5701 [12] [13] [14] [15] . Additionally, the HIV-specific CD8 þ T-cell response in BÃ57 þ LTNP/elite controller patients is highly focused upon HIV peptides restricted by this allele, suggesting that immune-mediated control is not due to a gene in linkage disequilibrium with BÃ57, but rather directly involves the B57 molecule [16, 17] . In addition, the LTNP/elite controller macaque model has provided direct evidence for the role of the CD8 þ T-cell response in mediating immunologic control in this setting [18] . Depletion of CD8 þ T cells by administration of an anti-CD8 monoclonal antibody results in a loss of restriction of SIV replication in these animals. As antibody levels fall and CD8 þ T cells rebound, immunologic control is restored [18] . Taken together, there is now a large body of evidence indicating that the CD8 þ T-cell response is responsible for immunologic control in the vast majority of LTNP/elite controllers.
Qualitative features of effective HIV-specific CD8 R T cells in long-term nonprogressors/ elite controllers Over the past decade, new tools have permitted an extensive characterization of the HIV-specific CD8 þ T-cell response of LTNP/elite controllers. As a result, a number of features of HIV-specific CD8 þ T cells that might account for control of virus replication have been eliminated from the list of possibilities. There is now general agreement that LTNP/elite controllers are not distinguished from progressors on the basis of the frequencies of HIV-specific CD8 þ T cells in the peripheral blood (reviewed in [19] ) [17, 20] . In addition, the CD8 þ T-cell response of LTNP/elite controllers is not differentiated from that of progressors on the basis of specificity or greater breadth (reviewed in [19] and [21] ) [16, 17, 20] . Differences in functional avidity have also not been reliably observed [8, [22] [23] [24] [25] . In addition, the same escape mutations have been found at comparable frequencies within immunodominant epitopes of sequences derived from HLA-BÃ57 þ LTNP/elite controllers and progressors [5, 7, 8, 23, 25] . Furthermore, there is no difference between the CD8 þ T cells of LTNP/ elite controllers and progressors in the ability to recognize the autologous virus [23, 24] . Taken together, these observations strongly suggest that insufficient recognition of the patient's autologous virus is not the mechanism responsible for the vast differences in immunologic control between progressors and LTNP/elite controllers. Instead, these findings suggest that qualitative features of the CD8 þ T-cell response mediate immunologic control of HIV in LTNP/elite controllers.
Although work since the late 1990s has continued to support that immunologic control of HIV in LTNP is due to qualitative features of the host immune response, it was also clear that these qualitative features were not being measured by even the most advanced assays. More recently, some differences in qualitative features of the ]. The importance of proliferative capacity in the control or elimination of antigen may extend beyond lentiviral infection. Proliferative capacity has been observed to be an important correlate of a successful immune response in lymphocytic choriomeningitis virus (LCMV) infection of mice, hepatitis C infection in humans, and passive transfer therapy studies of melanoma in humans [38] [39] [40] [41] .
Association between perforin expression and immunologic control
The greater ability of the HIV-specific CD8 þ T cells of LTNP/elite controllers to proliferate compared to progressors is paralleled by or possibly linked to the ability to increase the perforin content of cytotoxic granules. When examined directly ex vivo, HIV-specific CD8 þ T cells from LTNP/elite controllers and progressors have low or absent perforin expression [22, [42] [43] [44] [45] . However, following stimulation, the HIV-specific CD8 þ T cells of LTNP/elite controllers were found to greatly increase perforin expression over 3-6 days. In contrast, the HIVspecific CD8 þ T cells of progressors proliferate poorly and have only a limited ability to upregulate perforin over the same time.
Recent data suggest that perforin expression in virusspecific CD8 þ T cells can be measured more rapidly after restimulation [46, 47] 
Association between cytotoxic granule contents and cytotoxicity
For some time, it remained unclear whether differences between LTNP/elite controllers and progressors in the ability to increase the contents of cytotoxic granules translated into greater cytotoxic capacity. Most HIVspecific CD8 þ T cells isolated from the peripheral blood have very low amounts of perforin and have been observed to be poorly cytotoxic [22, 42, 44, 53] . In addition to perforin, LTNP/elite controllers were found to have a greater ability to upregulate granzyme B following stimulation [53] . No differences have been found, however, in the ability of cells from these two patient groups to degranulate [51 ,53] . Recently, using an assay designed to measure cytotoxic capacity on a per-cell basis, HIVspecific CD8 þ T cells of LTNP were observed to mediate rapid and efficient elimination of HIV-infected CD4 þ T-cell targets via the granule-exocytosis pathway in contrast to the responses observed with the cells of progressors [53] . ART did not restore cytotoxic capacity in progressors, which suggested that loss of these functions is likely not simply a consequence of high-level viremia during the chronic phase of infection [28, 53] . In several studies, cytotoxic capacity has now been very strongly associated with perforin contents of HIV-specific CD8 þ T cells [28, 53, 54 ] . Taken together, these lines of evidence suggest that an important correlate of HIVspecific CD8 þ T-cell-mediated control of viremia in LTNP/elite controllers is the long-term maintenance of perforin-mediated effector activity.
The disruption of multiple different functions of HIVspecific CD8
þ T cells of progressors, such as proliferation and expression of cytolytic granule-associated proteins, may suggest that the underlying defect(s) in effector functionality lie in the elements controlling their expression. For example, we have recently found that HIVspecific CD8 þ T cells from LTNP/elite controllers express higher levels of the transcription factor T-bet compared to progressors [55] . This T-box transcription factor has previously been associated with CD8 þ T-cell effector function and differentiation in both mice and humans [29, 56] .
Potential importance for vaccines and immunotherapies
One of the goals for the study of LTNP/elite controllers is to provide a better understanding of the mechanisms that could be exploited in T-cell-based vaccines and immunotherapies. It is not necessarily the case that control of HIV induced by a T-cell-based vaccine would be mediated through similar mechanisms to those operative in LTNP/elite controllers. However, there are some emerging data to suggest that some similarities exist. As noted above, HLA B5701-restricted cells were found to be preferentially expanded in volunteers with this allele following a canarypox-HIV recombinant vaccination [35] . Similar HLA associations were recently observed in the large efficacy trial of the Merck Ad5 trivalent vaccine or STEP trial [57] . Greater CD8 þ T-cell responses to Gag were strongly associated with HLA B alleles associated with control of HIV in a genome-wide association study. In a separate study of the same vaccine, greater HIV-specific CD8 þ T-cell cytotoxic capacity was observed in samples from patients with these same protective B alleles [58 ] . Taken together, it appears that similarities exist between observations in chronic infection and vaccination. However, because vaccines for HIV thus far have not induced a response that lowers viral load after infection, the predictive value of inducing a strong cytotoxic response cannot be assessed at this time. In addition, the precise mechanism by which a greater response is induced in patients with protective alleles remains incompletely understood.
Conclusion
Considerable progress has been made over the past decade in understanding the mechanism(s) by which LTNP/elite controllers might control HIV replication. In the last few years, a series of observations has come from several different labs that has resulted in a more cohesive paradigm for understanding immunologic control. Greater ability of the cells of LTNP/elite controllers compared to those of progressors to increase their cytotoxic granule contents and, thereby, increase their cytotoxic capacity appear to be the HIV-specific CD8 þ T-cell functions that are most clearly associated with immunologic restriction of HIV replication. Parallel observations in vaccinees underscore the potential implications of these observations for T-cell-based vaccines for HIV. 
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